S100A9 and glioma: We have previously shown that serum from glioma patients contains increased levels of S100A8/9 compared to healthy individuals, suggesting that MDSCs in glioma patients could gain a more suppressive phenotype due to enhanced Siglec-3–S100A9 interactions [13].